Ce diaporama a bien été signalé.
Nous utilisons votre profil LinkedIn et vos données d’activité pour vous proposer des publicités personnalisées et pertinentes. Vous pouvez changer vos préférences de publicités à tout moment.


150 vues

Publié le

  • Soyez le premier à commenter

  • Soyez le premier à aimer ceci


  1. 1. RESEARCH LETTER Concomitant 11p15.4-p15.5 Duplication and Terminal 22q13.33 Deletion in a Patient with Features of Beckwith–Wiedemann Syndrome Jess F. Peterson,1,2 * David P. Bick,3,4 Gabrielle C. Geddes,3 Julie McCarrier,3 John W. Grignon Jr,2 Brett Chirempes,4 Ulrich Broeckel,3,5 Fatima Abidi,6 Richard C. Rogers,6 Luigi Boccuto,6 Barbara DuPont,6 and Peter vanTuinen1,2 1 Department of Pathology, Medical College of Wisconsin, Milwaukee, Wisconsin 2 Wisconsin Diagnostic Laboratories, Milwaukee, Wisconsin 3 Department of Pediatrics, Section of Genetics, Medical College of Wisconsin, Milwaukee, Wisconsin 4 Advanced Genomics Laboratory, Children’s Hospital of Wisconsin, Milwaukee, Wisconsin 5 Department of Pediatrics, Section of Genomic Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin 6 Greenwood Genetic Center, Greenwood, South Carolina Manuscript Received: 24 April 2016; Manuscript Accepted: 10 August 2016 TO THE EDITOR: Beckwith–Wiedemann syndrome (BWS, OMIM 130650) is a clinically heterogeneous pediatric overgrowth disorder that can be attributed to various molecular etiologies [Choufani et al., 2013; Mussa et al., 2015]. Clinical features of BWS can include macroglossia, organomegaly, omphalocele, earlobe creases and pits, and symmetric or asymmetric growth that continues throughout childhood [Choufani et al., 2013; Mussa et al., 2016]. Importantly, children with BWS have an increased risk for embryonal tumors, including Wilms tumor, hepatoblastoma, neuroblastoma, rhabdomyosarcoma, and adrenocortical carci- noma [Choufani et al., 2013; Mussa et al., 2016]. While 98–99% of BWS cases result from the unbalanced expression of imprinted genes on the 11p15.5 region due to point mutations, epigenetic or genomic alterations, approximately 1–2% are due to cyto- genetic rearrangements [Choufani et al., 2013; Mussa et al., 2015]. Deletions involving the chromosome region 22q13.33, also known as Phelan–McDermid syndrome (PMS, OMIM 606232), are the result of either de novo terminal or interstitial deletions, or less commonly by unbalanced chromosomal rearrangements in- volving 22q13.33 [Wilson et al., 2003; Dhar et al., 2010; Misceo et al., 2011; Phelan and McDermid, 2012; Macedoni-Luksic et al., 2013]. Clinical features of PMS are highly variable and can include global developmental delay, intellectual impairment, hypotonia, severely delayed or absent speech, autism, or autistic-like behavior, and seizures [Phelan and McDermid, 2012]. The PMS proposed critical region (22q13.33) includes SHANK3, ACR, and RABL2, although many other genes in larger deletions may have a pheno- typic role. Recently, several studies have narrowed the PMS critical region to the SHANK3 gene [Dhar et al., 2010; Macedoni-Luksic et al., 2013], which also appears to be the most likely candidate for neurological impairments [Luciani et al., 2003; Wilson et al., 2003; Phelan and McDermid, 2012]. We report a 6-week-old Caucasian female with a complex karyotype involving rearrangements between chromosomes 11, 22, and an unknown acrocentric chromosome resulting in an 11p15.4-p15.5 duplication, terminal 22q13.33 deletion, and marker chromosome. While the 11p15.4-p15.5 duplication is located on the distal long arm of a bisatellited chromosome 22, the marker chromosome is thought to be a remnant of the unknown acrocentric chromosome. To our knowledge, this is Conflicts of interest: The authors have no conflict of interest to declare. Ã Correspondence to: Jess F. Peterson, M.D., Department of Pathology, Medical College of Wisconsin, Froedtert/MCW Laboratory Building, 9200 W Wisconsin Ave, Milwaukee, WI 53226. E-mail: jepeterson@mcw.edu Article first published online in Wiley Online Library (wileyonlinelibrary.com): 23 August 2016 DOI 10.1002/ajmg.a.37939 How to Cite this Article: Peterson JF, Bick DP, Geddes GC, McCarrier J, Grignon JW Jr, Chirempes B, Broeckel U, Abidi F, Rogers RC, Boccuto L, DuPont B, vanTuinen P. 2016. Concomitant 11p15.4-p15.5 duplication and terminal 22q13.33 deletion in a patient with features of Beckwith–Wiedemann syndrome. Am J Med Genet Part A 170A:3348–3351. Ó 2016 Wiley Periodicals, Inc. 3348
  2. 2. the first clinical report of a patient with cytogenetic abnormalities consistent with BWS (11p15.4-p15.5 duplication) and a terminal 22q13.33 deletion partially disrupting the SHANK3 gene. The patient was referred to the pediatric genetics clinic due to macrosomia and congenital macroglossia. She was born to a 31-year-old, G2P2002 mother and a 28-year-old father. Following an uncomplicated vaginal delivery at 40 weeks gestation, neonatal complications included hypoglycemia (35 mg/dl). Her birth weight was 5.67 kg (98.68% based on WHO weight-for-age data), length was 59.7 cm (99.35% based on WHO length-for-age data), and head circumference was 43 cm (99.98% based on WHO head circumference-for-age data). A complete physical exam was per- formed and revealed the following clinically significant features: broad nasal bridge, macroglossia, hepatomegaly (3–4 cm below the costal margin), and central hypotonia with increased tone in the periphery (Fig. 1A and B). An abdominal ultrasound was per- formed at an outside hospital and reported normal abdominal structures with no evidence of suprarenal mass. Family history includes an older sister and parents who are all phenotypically normal and of normal intelligence. There is no family history of birth defects, learning disabilities, genetic diseases, recurrent miscarriage, or consanguinity. Classical cytogenetic analysis was performed on phytohemag- glutinin (PHA) stimulated lymphocytes from a peripheral blood specimen. All 20 cells indicated a female with a bisatellited chro- mosome 22. In addition, 13 of the 20 cells contained a small marker chromosome (Fig. 1C). Fluorescence in situ hybridization (FISH) was performed on metaphase cells that contained the bisatellited chromosome 22 and marker chromosome using the BAC probe RP11-27N2 (Empire Genomics, Buffalo, NY), located within the duplicated region of 11p15.4-p15.5. Hybridization of the RP11-27N2 probe was observed on the short arms of both copies of chromosome 11, in addition to the bisatellited chromosome 22 (Fig. 1D). Hybridization of RP11-27N2 was not observed on the marker chromosome. Array comparative genomic hybridization (aCGH) analysis was performed on purified DNA from the proband using the CytoScan HD microarray (Affymetrix, Santa Clara, CA), and scanned with a FIG. 1. (A and B) Proband at 6-weeks of age. Note the broad nasal bridge, macroglossia, and enlarged abdomen. (C) Representative metaphase cell from a peripheral blood specimen. Arrows point to both normal copies of chromosome 11, one normal copy of chromosome 22, a bisatellited chromosome 22, and a marker chromosome. (D) Sequential FISH analysis of the representative metaphase cell (see C) using a locus-specific probe (RP11-27N2) targeting chromosomal region 11p15.4-p15.5. Positive hybridization (arrows) was observed on both copies of chromosome 11 in addition to the bisatellited chromosome 22. The marker chromosome (see C) is thought to be a remnant of an unknown acrocentric chromosome. (Color figure can be seen in the online version of this article, available at http://wileyonlinelibrary.com/journal/ ajmga). PETERSON ET AL. 3349
  3. 3. Genechip Scanner 3000 (Affymetrix). Microarray analysis revealed a concomitant 10.3 Mb duplication in the 11p15.4-p15.5 region, (Fig. 2A) and a 53 kb heterozygous deletion in the 22q13.33 region (Fig. 2B). The 11p15.4-p15.5 duplication region contained a total of 380 genes including 143 OMIM genes, and the 22q13.33 deletion region contained a total of five genes including two OMIM genes, SHANK3 and ACR. In addition, a methylation-specific multiplex ligation-dependent probe amplification assay (MS-MLPA) (MRC- Holland) was utilized to determine the methylation status of imprinting control regions 1 and 2 (ICR1 and ICR2). The assay confirmed the duplication between probes H19-5 and CDKN1C-1b [HHA1] on chromosome 11p15.4-p15.5, and showed hyperme- thylation of ICR1 and hypomethylation of ICR2, a pattern consis- tent with a double paternal copy of the 11p15.4–15.5 region resulting in BWS. Pyrosequencing was subsequently performed and confirmed these results. To confirm the partial SHANK3 deletion, purified DNA from the proband was analyzed at an outside institution (Greenwood Genetic Center, Greenwood, SC) using a custom exon-specific array (Agilent Technologies, Santa Clara, CA) and scanned with a SureScan Microarray Scanner (Agilent Technologies). Microarray analysis revealed a partial SHANK3 deletion spanning exons 17–22 located within the 22q13.33 region (Fig. 2C). Importantly, the exon-specific array includes SHANK3 but no other genes within the terminal region of 22q13.3. The final karyotype of the proband was: mos 47,XX,22qs,þmar[13]/46,XX,22qs[7].ish(22qs) (RP11-27N2 þ).arr[hg19] 11p15.5p15.4(230,615–10,552,968) x3,22q13.33(51,144,903–51,197,716)x1. Parental genetic studies included classical cytogenetic analysis. Both parents had normal karyotypes and were not carriers of a balanced translocation or marker chromosome. Beckwith–Wiedemann and Phelan–McDermid syndromes are both rare with an estimated prevalence of 1/13,700 for BWS [Choufani et al., 2013], and while the incidence of PMS has not been determined, approximately 1,200 cases have been diagnosed world-wide [Kolevzon et al., 2014]. While multiple molecular etiologies resulting in BWS have been described, the majority of which involve epigenomic or genomic alterations of genes within imprinting control centers 1 (IC1) or 2 (IC2), approximately 1–2% of cases are attributed to 11p15.5 duplications [Choufani et al., 2013; Mussa et al., 2016]. The diagnosis of BWS has tremendous clinical significance as these patients have an increased risk of FIG. 2. (A) Array CGH profile showing a 10.3 Mb duplication of 11p15.4-p15.5 region. (B) Array CGH profile showing a 53 kb terminal deletion of 22q13.33 regions. (C) Custom exon-specific array results demonstrating a partial SHANK3 deletion spanning exons 17–22. (Color figure can be seen in the online version of this article, available at http://wileyonlinelibrary.com/journal/ajmga). 3350 AMERICAN JOURNAL OF MEDICAL GENETICS PART A
  4. 4. embryonal tumors that require early tumor surveillance protocols [Mussa et al., 2016]. Deletions spanning the 22q13.33 region that include the SHANK3, ACR, and RABL2 genes result in PMS [Luciani et al., 2003; Wilson et al., 2003]. In addition, intragenic SHANK3 deletions have also been reported to produce the full clinical spectrum of PMS [Misceo et al., 2011; Macedoni-Luksic et al., 2013]. The prompt diagnosis of PMS is also of importance, as screening protocols for hypothyroidism, hearing impairment, arachnoid cysts, and renal anomalies are recommended [Phelan and McDermid, 2012]. Our case is unique in that, it is the first reported concomitant 11p15.4-p15.5duplicationand22q13.33deletionthatlikelyresulted from a complex chromosomal rearrangement involving chromo- somes 11, 22, and an unknown acrocentric chromosome. Our patient presented with the typical neonatal findings of BWS. The clinical significance of the 22q13.33 rearrangement will not be known until later since most of the common phenotypic features associated with PMS, such as periorbital fullness, hypohidrosis and heat intolerance, dysplastic nails, intellectual disability, autism, and seizures present in early childhood. The only identifiable feature of PMS presented by the patient at the time of the evaluation is central hypotonia, although this is usually more severe in typical cases with 22q13.33 deletions and it persists in adulthood, unlike in BWS. In addition, the molecular abnormalities are also rare for each respec- tive syndrome (11p15 duplication for BWS, unbalanced chromo- somal rearrangement for PMS). Furthermore, this case illustrates that a multifaceted approach may be necessary to resolve complex chromosomal rearrangements in constitutional disorders. REFERENCES Choufani S, Shuman C, Weksberg R. 2013. Molecular findings in Beck- with-Wiedemann syndrome. Am J Med Genet Part C Semin Med Genet 163C:131–140. Dhar SU, del Gaudio D, German JR, Peters SU, Ou Z, Bader PI, Berg JS, Blazo M, Brown CW, Graham BH, Grebe TA, Lalani S, Irons M, Sparagana S, Williams M, Phillips JA, 3rd, Beaudet AL, Stankiewicz P, Patel A, Cheung SW, Sahoo T. 2010. 22q13.3 deletion syndrome: Clinical and molecular analysis using array CGH. Am J Med Genet Part A 152A:573–581. Kolevzon A, Angarita B, Bush L, Wang AT, Frank Y, Yang A, Rapaport R, Saland J, Srivastava S, Farrell C, Edelmann LJ, Buxbaum JD. 2014. Phelan-McDermid syndrome: A review of the literature and practice parameters for medical assessment and monitoring. J Neurodev Disord 6:39. Luciani JJ, de Mas P, Depetris D, Mignon-Ravix C, Bottani A, Prieur M, Jonveaux P, Philippe A, Bourrouillou G, de Martinville B, Delobel B, Vallee L, Croquette MD, Mattei MG. 2003. Telomeric 22q13 deletions resulting from rings, simple deletions, and translocations: Cytogenetic, molecular, and clinical analyses of 32 new observations. J Med Genet 40:690–696. Macedoni-Luksic M, Krgovic D, Zagradisnik B, Kokalj-Vokac N. 2013. Deletion of the last exon of SHANK3 gene produces the full Phelan- McDermid phenotype: A case report. Gene 524:386–389. Misceo D, Rødningen OK, Barøy T, Sorte H, Mellembakken JR, Strømme P, Fannemel M, Frengen E. 2011. A translocation between Xq21.33 and 22q13.33 causes an intragenic SHANK3 deletion in a woman with Phelan-McDermid syndrome and hypergonadotropic hypogonadism. Am J Med Genet Part A 155A:403–408. Mussa A, Russo S, Larizza L, Riccio A, Ferrero GB. 2015. (Epi)genotype- phenotype correlations in Beckwith-Wiedemann syndrome: A paradigm for genomic medicine. Clin Genet 89:403–415. Mussa A, Di Candia S, Russo S, Catania S, De Pellegrin M, Di Luzio L, Ferrari M, Tortora C, Meazzini MC, Brusati R, Milani D, Zampino G, Montirosso R, Riccio A, Selicorni A, Cocchi G, Ferrero GB. 2016. Recommendations of the scientific committee of the Italian Beck- with-Wiedemann syndrome association on the diagnosis, management and follow-up of the syndrome. Eur J Med Genet 59:52–64. Phelan K, McDermid HE. 2012. The 22q13.3 deletion syndrome (Phelan- McDermid syndrome). Mol Syndromol 2:186–201. Wilson HL, Wong AC, Shaw SR, Tse WY, Stapleton GA, Phelan MC, Hu S, Marshall J, McDermid HE. 2003. Molecular characterization of the 22q13 deletion syndrome supports the role of haploinsufficiency of SHANK3/PROSAP2 in the major neurological symptoms. J Med Genet 40:575–584. PETERSON ET AL. 3351